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Edited by Felix WielandAbstract Heat shock protein 90 (Hsp90) is a molecular chaper-
one which modulates several signalling pathways within a cell.
By applying co-immunoprecipitation with endogeneous Hsp90,
we were able to identify 39 novel protein interaction partners
of this chaperone in human embryonic kidney cells (HEK293).
Interestingly, levels of DNA-activated protein kinase catalytic
subunit, an Hsp90 interaction partner found in this study, were
found to be sensitive to Hsp90 inhibitor treatment only in HeLa
cells but not in HEK293 cells referring to the tumorgenicity of
this chaperone.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Heat shock protein 90 (Hsp90) is an abundant, constituti-
vely expressed chaperone (1–2% of total cellular protein under
non-stress conditions). The current opinion is that Hsp90
binds to a restricted set of substrates rather than generally to
unfolded proteins. It seems to be specialised in stabilising
metastable regions, such as open ligand binding pockets, by
keeping them in a ‘‘holding’’ position, thus, preventing their
collapse or aggregation [1].
Hsp90 is an ATP-dependent chaperone. Although the ATP-
ase activity of human Hsp90 is barely detectable as compared
to that of the yeast or of the bacterial homologue, it becomes
stimulated by co-chaperones or substrates [2]. Binding of
Hsp90 to substrates is selectively inhibited by benzoquinone
ansamycins (geldanamycin and derivatives) and radicicol,
which bind to the ATP-binding pocket with a much higher
aﬃnity than ATP [3].
Of the approximatively 100 client proteins of Hsp90 known
so far, a considerable number are overexpressed or mutated in
malignous tumours [4]. It is indicative that the ﬁrst client pro-
tein of Hsp90 to be identiﬁed in vivo in vertebrates was the
oncogenic viral tyrosine kinase v-Src [8]. One of the reasons
for this preferential interaction is probably due to the destabil-
ising eﬀects of amino acid mutations. In accordance with thisAbbreviations: Hsp90, heat shock protein 90; HEK293, human embry-
onic kidney cells; DNA-PKcs, DNA-activated protein kinase catalytic
subunit; co-IP, co-immunoprecipitation
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doi:10.1016/j.febslet.2005.10.020hypothesis, it has been recently shown that in vitro the intrinsic
stability of v-Src is signiﬁcantly reduced compared to the cellu-
lar counterpart c-Src [5].
Suppressing the interaction between Hsp90 and client pro-
teins represents a promising antitumoral approach [4]. Yet,
the discovery of novel Hsp90 substrates occurs rather inciden-
tally than rationally. A global picture of Hsp90-modulated
functional frameworks in vivo would greatly improve long-
term challenges such as the development of more sophisticated
drugs which for example might selectively suppress Hsp90
interactions situated on exclusive nodes of signal transduction
pathways.
Here, we present a proteomic approach by which ‘‘all’’ Hsp90
clients can be identiﬁed and which can be further improved
towards the detection of low-abundant as well as transient
substrates of this therapeutically important chaperone.2. Materials and methods
Unless otherwise described, reagents, chemicals and antibodies were
purchased from Sigma (St. Louis, MO, USA).
2.1. Cell preparation
Human embryonic kidney cells (HEK293) and HeLa cells were
grown at 37 C and 5% CO2 in DMEM supplemented with 10% fetal
calf serum (PAA, Pasching, Austria). Conﬂuent cells were washed once
with PBS, harvested with a dish scraper, stained with trypan blue and
viability was determined with a hemocytometer (Brand, Wertheim,
Germany). For inhibition of Hsp90, cells were treated with 20 lM rad-
icicol, or with DMSO as a control, respectively.
2.2. Immunoprecipitation
107 HEK293 cells were used for each experiment. Cells were sus-
pended in 500 ll lysis buﬀer (20 mM Tris, 2.5 mM NaCl, 1% Triton
X-100, pH 7.4) supplemented with protease inhibitor mix, disrupted
for 20 0 at 4 C on a rotary shaker and centrifuged at 13000 · g. The
pellet was discarded and 4 ll of anti-Hsp90 antibody (clone AC68,
Stressgen, San Diego, USA) were added except to the control samples.
The mixture was incubated overnight at (ca. 15 h) 4 C on a rotary sha-
ker. A Protein-G agarose resin was then added and samples were incu-
bated for further 3 h at 4 C. After that, samples were centrifuged, the
supernatant was removed and the protein-G agarose resin was washed
5 times with washing buﬀer (50 mM Tris, 150 mM NaCl, 0.1% Triton
X-100, pH 7.4). La¨mmli buﬀer was added directly to the protein-G
agarose, heated at 95 C, probes were run on a SDS–PAGE gel and
ﬁnally detected by silver-staining.
2.3. In-gel protein digestion and mass spectrometry
Bands to be analysed were prepared as described in [6]. Brieﬂy,
bands of interest were excised, soaked sequentially with NH4HCO3
and NH4HCO3/acetonitrile, and dehydrated with acetonitrile (Fisher
Scientiﬁc, Loughborough, UK). Each sample was then subjected to
reduction of the disulﬁde bonds with DTT at 54 C and to alkylation
with iodacetamide. Bands were then washed again with NH4HCO3,blished by Elsevier B.V. All rights reserved.
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(Eppendorf, Hamburg, Germany) and either stored at 80 C or
immediately used for proteolytic digestion. For this purpose, samples
were rehydrated in NH4HCO3, subjected to tryptic digestion overnight
and peptides were gel-extracted. Nano-HPLC–MS/MS sequencing and
peptide database search were performed as previously described [6].
2.4. Detection of DNA-PKcs in cytosolic and nuclear cell lysates
For the inhibition of Hsp90, cells were treated with 20 lM radicicol,
or with DMSO as a control, respectively, and incubated in serum-free
medium for diﬀerent periods. For the preparation of the nuclear
extracts, cells were harvested as described above, resuspended in buﬀer
containing 10 mM HEPES, 50 mM NaCl, 0.5 M sucrose, 0.1 mM
EDTA and 0.5% Triton-X100, pH 7.9, incubated on ice for 5 0, and
centrifuged at 1000 · g. The cytosolic supernatant was stored sepa-
rately. To obtain the nuclear extract, the pellet was resuspended in
buﬀer containing 10 mM HEPES, 500 mM NaCl, 0.1 mM EDTA,
0.1% Igepal, pH 7.9, rotated for 15 0 at 4 C, and centrifuged at
14000 · g for 10 0 at 4 C.
Samples of the cytosolic and the nuclear fractions were run on a 8%
SDS–PAGE gel and blotted on a Hybond nitrocellulose membrane
(Amersham Biosciences, Uppsala, Sweden). Marker bands were visual-
ised by staining with Ponceau Red. The membrane was further incu-
bated ﬁrst with anti-DNA-activated protein kinase catalytic subunit
(DNA-PKcs) antibody (clone 18-2, EMD Biosciences, Darmstadt,
Germany) and then with horseradish peroxidase-coupled anti-mouse-
antibody. DNA-PKcs was detected by treatment with ECL solution
(Amersham Pharmacia, Uppsala, Sweden) and ﬁnal exposure to a
Kodak X-Omat AR ﬁlm for visualisation. For the control detection
of vinculin, the same procedure was repeated and anti-vinculin (clone
hVIN-1) was used for immunoblotting of the cytosolic fractions.3. Results and discussion
To obtain a Hsp90/substrate-interaction map, we performed
co-immunoprecipitation (co-IP) experiments in cytosolic cell
lysates of conﬂuent HEK293 cells using antibodies directed
against Hsp90 as a bait. We preferred to target endogenous
Hsp90 rather than to add exogenous, recombinantly expressed
Hsp90, to our preparation, since endogenous conformations
and post-translational modiﬁcations of Hsp90 might be requiredFig. 1. (A) 10% SDS–PAGE of proteins Hsp90 co-IPed from HEK293 cell lys
1: controls (no antibody). (B) 8% SDS–PAGE gel of proteins Hsp90 co-IPedfor eﬃcient interactions with client proteins. We further used
an antibody which was able to recognise both Hsp90 a and
b isoforms. Due to the transient/labile nature of Hsp90-client
complexes, several conditions for IP-ing these complexes were
tested. For this purpose, the inﬂuence of ionic strength, pH
and temperature as well as of additives like detergents and
metal ions was tested. The ﬁnally optimised conditions for
Hsp90 co-IP are given in Section 2.
The protein mixture which co-IPed together with Hsp90 was
separated on SDS–PAGE and the detected bands were, after
in-gel trypsinisation, analysed by nano-HPLC–MS/MS. Fig. 1
shows two typical silver-stained SDS–PAGE gels obtained from
an Hsp90 co-IPed HEK293 lysate. After washing with 150 mM
NaCl, only few bands were visible on the control lane (Fig. 1A,
lane 1) indicating that background contaminations derived from
unspeciﬁc binding to protein-G had been eﬃciently removed.
As summarised in Table 1, most of the proteins identiﬁed
are metabolic enzymes (synthetases, glycolytic enzymes), ribo-
somal subunits, translational proteins (tRNA synthetases, ini-
tiaton/elongation factors), structural proteins and chaperones
(two of the identiﬁed proteins, spot Nos. 38 and 39, have no
annotated function yet). Among the chaperones identiﬁed,
the interaction between Hsp90 and Hsp70 is well documented
and represents one of the best investigated chaperoning cycles
[1,7]. Our inability to detect further Hsp90 co-chaperones by
our pull-down method may be due to the fact that the anti-
Hsp90 antibody in the IP experiments displaced co-chaperones
from Hsp90 by competiting for shared epitopes on the chaper-
one. In addition, the transient nature of the Hsp90/co-chaper-
one complexes combined with the low abundancy of the latter
proteins rendered detection of these complexes diﬃcult.
The interaction with glycolytic enzymes was previously unre-
ported for Hsp90 but might be important to guarantee a higher
production of ATP under stress conditions. Since Hsp90 was
recently suggested to be an ATP-sensor [8], the interaction
with glycolytic enzymes may also represent a feedback loop
for the regulation of the ATP synthesis.ates. M: molecular weight marker. Lane 2: 150 mMNaCl extract. Lane
from HEK293 cell lysates. Lane 1: 150 mM NaCl extract.
Table 1
Hsp90 co-IPed proteins from HEK293 cell lysates identiﬁed by nano-HPLC–MS/MS of in-gel tryptic digests (see Fig. 1) using the programmes





Name Principal function Interaction
reported
P08238 83133 Hsp90b Chaperone
1 P08107 70052 Hsp70-1 Chaperone Yes [1]
2 P17987 60344 T-complex protein 1, alpha subunit (Hsp60) Chaperone No
3 Q92598 96865 Hsp105 Chaperone No
4 P78527 469089 DNA-activated protein kinase, catalytic subunit DNA-repair No





6 O14980 123385 CRM1 protein (XPO1) Nuclear protein export No
7 P14618 57806 Pyruvate kinase, M1 isozyme Metabolic enzyme: ATP-production No
8 P00354 35876 Glyceraldehyde 3-phosphate dehydrogenase Metabolic enzyme: ATP-production No
9 P00558 44483 Phosphoglycerate kinase Metabolic enzyme: ATP-production No
10 P00338 36558 L-lactate dehydrogenase Metabolic enzyme: ATP-production No
11 P04075 39289 Fructose-bisphosphate aldolase Metabolic enzyme: ATP-production No
12 P40925 36295 Malate dehydrogenase Metabolic enzyme: gluconeogensis No
13 Q6P4U5 273397 Fatty acid synthase Metabolic enzyme No
14 P11586 101428 C-1-tetrahydrofolate synthase Metabolic enzyme No
15 Q9Y617 40423 Phosphoserine aminotransferase Metabolic enzyme: serine and
pyridoxine biosynthesis
No
16 Q9NR45 40308 Sialic acid synthase Metabolic enzyme:
lipopolysaccharide metabolism
No
17 P63261 41793 Actin gamma 1 Structural protein Yes [23]
18 P06753 32819 Tropomyosin, alpha-3 chain Structural protein Nob
19 P21333 280761 Filamin A Structural protein No
20 P35579 226532 Myosin heavy chain Structural protein Yes [23]
21 Q13813 284527 Spectrin alpha chain Structural protein No
22 Q14981 238274 Nuclear mitotic apparatus protein NuMA Structural protein No
23 P12814 103058 Alpha actinin Structural protein No
24 P22314 117849 Ubiquitin-activating enzyme E1 Proteasomal targeting Yes [24]
25 Q99460 105836 26S proteasome non-ATPase regulatory subunit 1 Proteolysis Yes [25]
26 Q6PEW2 28480 Proteasome beta 5 subunit Proteolysis Yes [25]
27 P49588 106801 Alanyl-tRNA synthetase Translational machinery No
28 Q6PI85 106039 Isoleucyl-tRNA synthetase Translational machinery Yes [9]
29 P13639 95207 Eukaryotic translation elongation factor 2 Translational machinery No
30 O15372 39930 Eukaryotic translation initiation factor 3,
gamma subunit
Translational machinery No
31 Q6IPD1 32914 Similar to laminin receptor 1 Ribosomal subunit No
32 P05388 34274 60S Acidic ribosomal protein P0 Ribosomal subunit Yesc [14]
33 P62753 28681 40S ribosomal protein S6 Ribosomal subunit No
34 P62701 29467 40S ribosomal protein S4, X isoform Ribosomal subunit No
35 P18124 29226 60S ribosomal protein L7 Ribosomal subunit Yesc [14]
36 P61247 29814 40S ribosomal protein S3a Ribosomal subunit No
37 P46777 34317 60S ribosomal protein L5 Ribosomal subunit Yesc [14]
38 Q9HB07 42445 MYG1 Unknown No
39 Q96KM8 42502 GA17 protein Unknown No
aInteractions between Hsp90 and, Ga0 and Ga12 have already been reported [26,27].
bTropomyosin inhibits binding of Hsp90 to actin [23].
cIt is not speciﬁed which of the 60S subunits interact with Hsp90.
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in this study supports a strong involvement of Hsp90 in gene
translation and protein expression. Hsp90 was previously
shown to interact with several tRNA-synthetases [9] although
the alanyl-tRNA-synthetase identiﬁed in our work (hit no. 27,
Table 1) has yet not been reported. In addition, interactions
between Hsp90 and eukaryotic elongation factor 2 kinase
(eEF-2 kinase) have been described recently [10] which might
indicate that Hsp90 acts as scaﬀold during the phosphoryla-
tion of eEF-2 (hit no. 29, Table 1) similar to NO-synthase
phosphorylation by Akt kinase [11].
In a very recent publication, Zhao et al. [12] report on the
Hsp90 chaperoning network in yeast. These authors used, in
addition to two-hybrid detection, TAP-tagging of Hsp90 to
trap clients of this chaperone which were subsequently identi-
ﬁed by MALDI-ToF ﬁngerprinting (only a smaller fraction ofthe client proteins were subjected to nano-LC–MS/MS sequen-
cing). By this means, Zhao et al. claim that 10% of the yeast
proteome interact with Hsp90. By using TAP-aﬃnity chroma-
tography combined with an almost unlimited protein supply,
the authors were able to also amplify low abundant Hsp90
clients like transcription factors. By our approach, however,
we have extended the Hsp90 interactome by human client pro-
teins which might play a role in disease (see below).
Unlike for Hsp70 [13], an immediate role of Hsp90 in folding
of nascent polypeptides has so far not been reported. However,
Hsp90 plays a crucial role during the nuclear export of 60S
ribosomal subunits [14] which might include the nuclear export
factor CRM1 (hit no. 6, Table 1). These considerations would
suggest a role for Hsp90 as a ‘‘joker’’ appointed to direct the
informational ﬂux between genome and proteome at several
levels.
Fig. 2. Inﬂuence of radicicol on the expression of DNA-PKcs.
Changes of DNA-PKcs levels in cytosolic and nuclear extracts of
HeLa cells (A) and HEK293 cells (C) treated with 20 lM radicicol, and
changes of vinculin levels in cytosolic extracts of HeLa cells (B) and
HEK293 cells (D) after the same treatment (control).
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potentially novel Hsp90-interacting proteins, we were not able
to detect ‘‘classical’’ Hsp90-substrates such as transcription
factors or src-family kinases [1]. This is obviously a demanding
task considering the low abundance, the rapid turnover and
the transient, sometimes cell speciﬁc expression pattern of
most of these proteins. Many Hsp90-substrates are overexpres-
sed only upon deﬁned (predominantly stress) stimuli during
cell life. Cell cycle control kinases or other proteins devoted
to cell proliferation for example, might be strongly downregu-
lated in conﬂuent cells used in our studies, while being strongly
upregulated during tumorigenic stress. In addition, low aﬃnity
complexes might have been disrupted during sample prepara-
tion. In particular, ‘‘mature’’ hsp90-substrates will have a
reduced aﬃnity to Hsp90 compared to their partially unfolded
precursors whereby they could escape their bait during sample
preparation (this also applies to kinetically instable com-
plexes). Finally, high abundant substrates in the preparations
might compete for Hsp90 binding sites thereby saturating the
chaperone in the lysate or just displacing low abundance
substrates by law of mass action. Thus, the picture presented
here represents a snapshot of Hsp90 engaged in its ‘‘house-
keeping’’ role, rather than ‘‘in functional/pathological action’’
(e.g., chaperoning signal transduction).
For these reasons, we are currently undertaking a reﬁnement
of the experimental set-up, in which (a) transient endogenous
Hsp90-complexes in diﬀerent cell lines (including primary
tumour tissues) are stabilised by using Hsp90-complex stabilis-
ers such as molybdate [15] and/or cross-linkers [16,17], and (b)
low abundant clients are ampliﬁed (e.g., by depletion of high
abundant substrates). The most important requirement, how-
ever, will be the discrimination of functional from unspeciﬁc
interactions, i.e., the physiologic validation of our hits. The
deﬁnition of ‘‘Hsp90 function’’ is an ATPase dependent mod-
ulation of client protein maturation [1]. A widely appreciated
method of functional Hsp90-proﬁling is the use of Hsp90-
ATPase inhibitors such as geldanamycin, radicicol or novobi-
ocin, which force the disruption of Hsp90-complexes in cells.
As a consequence, substrates which are no longer chaperoned
by Hsp90 become susceptible to degradation [18]. To show
that this method can be implemented as a successive step to
our pull-down proteomic experiments, we selected the kinase
DNA-PKcs (hit no. 4, Table 1) and investigated its expression
proﬁle in cells treated with radicicol. We focussed our atten-
tion onto this protein for two reasons. First, kinases are pref-
erential substrates of Hsp90 [1]. Second, DNA-PKcs contains
several potential PEST sequences (according to the algorithm
PESTﬁnd [19]) which are typical for molecules degraded by
the proteasome like for most of the Hsp90-substrates [20].
DNA-PKcs is a 450 kDa serine/threonine kinase with key roles
in non-homologous DNA-end joining as well as in V(D)J
recombination [21]. It is functional in the nucleus where it be-
comes active as a kinase upon binding to double stranded
DNA, forming an active complex with the partner proteins
Ku70 and Ku80 and phosphorylating other proteins involved
in DNA repair [21]. Using an antibody directed against
DNA-PKcs, we were able to detect the kinase in cytosolic as
well as in nuclear extracts. Surprisingly, we could not observe
a signiﬁcant inﬂuence of radicicol on the expression pattern of
DNA-PKcs in HEK293 cells. As shown in Fig. 2C, cytosolic
levels of DNA-PKcs remained almost unchanged. However,
DNA-PKcs levels in the cytosol of HeLa cells (which constitu-tively express Hsp90 and which exhibited a very similar Hsp90
co-IP pattern as the HEK293 cells, data not shown) were sig-
niﬁcantly inﬂuenced by the treatment with inhibitor (Fig. 2A).
After 22 h, the cytosolic fraction of the kinase was nearly com-
pletely degraded. As a control, the expression of vinculin, an
abundant and ubiquitous structural protein, was monitored
and found not to be altered by the presence of radicicol during
the course of the experiment (Fig. 2B and D). These results
support the recent discovery that Hsp90/substrate complexes
are more sensitive to the eﬀects of inhibitors in tumour cells
than in healthy cells, which in turn seems to be due to a higher
aﬃnity of tumoral Hsp90 for these inhibitors [22]. In addition,
the observation that the nuclear fraction of DNA-PKcs was
not aﬀected by the treatment with radicicol (Fig. 2A and C)
indicates that at least in HeLa cells, DNA-PKcs might be sen-
sitive to Hsp90-complex destabilisation as long as it is set ‘‘on
hold’’ by Hsp90 in the cytosol for further activation. Whereas
the nuclear-located – and therefore fully active – kinase, might
no longer require the chaperoning aid of Hsp90, in a very sim-
ilar fashion to steroid receptors [15].
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